MRC1 and neoplasm: In contrast, triple combination therapy (pexidartinib, oncolytic adenoviruses, and anti-PD1 Ab) in mice inhibited TAM recruitment to the tumor and reprogrammed TAMs toward the M1 phenotype, in which the percentage of CD206+ TAMs was reduced [199].